aidsmap news story
Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could be components of future long-acting HIV treatment regimens, according to study results presented at CROI 2026.
Pharmacokinetic data showed that ViiV Healthcare’s investigational capsid inhibitor VH-499, ViiV’s next generation integrase inhibitor VH-184 and Gilead Sciences’ pipeline integrase inhibitor GS-3242 could potentially be administered by injection just twice a year. All three drugs were safe and generally well tolerated, and phase II studies are expected to start this year.
Read the full news story here.
View all aidsmap reports from CROI 2026
Source : aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.